Abogen announces that preliminary first-in-human (FIH) clinical data for ABO2203 has been selected for an oral presentation at the American Association for Cancer Research (AACR) Annual Meeting 2026, to be held April 17-22 in San Diego, California.

ABO2203, featuring clinical research conducted by Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, is an innovative mRNA-encoded CD3×CD19 T-cell engager (TCE) being evaluated for the treatment of patients with relapsed/refractory B-cell non-Hodgkin lymphoma. 

Abogen's Oral Presentation Details

• Session Title: CTMS03 - Advanced Cellular and Immune-Based Therapeutics

• Abstract Number: CT032

• Presentation Title: ABO2203, a messenger RNA encoding a CD3×CD19 T cell engager, for relapsed/refractory B cell non-Hodgkin lymphoma: Preliminary results from first-in-human study

• Date & Time: April 19, 2026 | 4:35 PM – 4:45 PM (PT)

• Location: Ballroom 20 AB, Upper Level, San Diego Convention Center